Literature DB >> 31696272

Underestimated fracture risk in postmenopausal women-application of the hybrid intervention threshold.

Y Wang1, S Yu2, C Hsu2, C Tsai3, T Cheng4,5.   

Abstract

This study evaluated the fragility fracture risk of Taiwanese postmenopausal women with osteopenia. With the incorporation of FRAX and hybrid intervention threshold (HIT), 25% of the participants had high fracture risk. We suggest intervention for fragility fracture for postmenopausal women should be guided by FRAX and HIT instead of bone mineral density alone.
INTRODUCTION: To explore the risk of fragility fracture in Taiwanese postmenopausal women with osteopenia using the hybrid intervention threshold (HIT) and Fracture Risk Assessment tool (FRAX).
METHODS: The Taiwan Osteoporosis Association (TOA) conducted a nationwide bone mineral density (BMD) survey between 2008 and 2011 using a bus equipped with a dual-energy X-ray absorptiometry (DXA) machine. All participants completed a structured questionnaire, which included the elements in the FRAX. Based on the results, the group made up of postmenopausal women with osteopenia was identified. In order to explore the risk of fragility fracture by HIT and FRAX among Taiwan postmenopausal women with osteopenia, the 10-year probability of fracture (FRAX score) and individual intervention threshold (IIT) in this group were calculated. If the FRAX score of a participant was higher than or equal to the IIT or fixed intervention threshold (FIT), the participant was considered as above the HIT (HIT could be reached by being over a threshold at either major osteoporotic fracture or hip fracture) and categorized as having a high FRAX fracture risk.
RESULTS: A total of 13,068 postmenopausal women were enrolled in the program. A total of 5743 (43.9%) participants had osteopenia, of which 1434 (25.0%) had high FRAX fracture risk.
CONCLUSIONS: One quarter of Taiwanese postmenopausal women with osteopenia had high fragility fracture risk evaluated by FRAX and HIT. Due to the poor sensitivity of BMD for fragility fracture, we suggest that intervention for fragility fracture for postmenopausal women should also be guided by FRAX and HIT instead of BMD alone.

Entities:  

Keywords:  FRAX; Intervention threshold; Menopause; Osteopenia

Mesh:

Year:  2019        PMID: 31696272     DOI: 10.1007/s00198-019-05201-5

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  32 in total

1.  Use of dual-energy X-ray absorptiometry (DXA) for diagnosis and fracture risk assessment; WHO-criteria, T- and Z-score, and reference databases.

Authors:  Hans P Dimai
Journal:  Bone       Date:  2016-12-29       Impact factor: 4.398

2.  The distribution of FRAX(®)-based probabilities in women from Japan.

Authors:  John A Kanis; Helena Johansson; Anders Odén; Eugene V McCloskey
Journal:  J Bone Miner Metab       Date:  2012-08-22       Impact factor: 2.626

3.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

Authors:  R M Neer; C D Arnaud; J R Zanchetta; R Prince; G A Gaich; J Y Reginster; A B Hodsman; E F Eriksen; S Ish-Shalom; H K Genant; O Wang; B H Mitlak
Journal:  N Engl J Med       Date:  2001-05-10       Impact factor: 91.245

4.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Authors:  U A Liberman; S R Weiss; J Bröll; H W Minne; H Quan; N H Bell; J Rodriguez-Portales; R W Downs; J Dequeker; M Favus
Journal:  N Engl J Med       Date:  1995-11-30       Impact factor: 91.245

5.  Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

Authors:  Steven R Cummings; Javier San Martin; Michael R McClung; Ethel S Siris; Richard Eastell; Ian R Reid; Pierre Delmas; Holly B Zoog; Matt Austin; Andrea Wang; Stepan Kutilek; Silvano Adami; Jose Zanchetta; Cesar Libanati; Suresh Siddhanti; Claus Christiansen
Journal:  N Engl J Med       Date:  2009-08-11       Impact factor: 91.245

6.  Bone mineral density thresholds for pharmacological intervention to prevent fractures.

Authors:  Ethel S Siris; Ya-Ting Chen; Thomas A Abbott; Elizabeth Barrett-Connor; Paul D Miller; Lois E Wehren; Marc L Berger
Journal:  Arch Intern Med       Date:  2004-05-24

7.  Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.

Authors:  John A Kanis; Helena Johansson; Anders Oden; Eugene V McCloskey
Journal:  Bone       Date:  2009-02-28       Impact factor: 4.398

8.  Ten-year fracture probability identifies women who will benefit from clodronate therapy--additional results from a double-blind, placebo-controlled randomised study.

Authors:  E V McCloskey; H Johansson; A Oden; S Vasireddy; K Kayan; K Pande; T Jalava; J A Kanis
Journal:  Osteoporos Int       Date:  2008-11-11       Impact factor: 4.507

9.  Clinician's Guide to Prevention and Treatment of Osteoporosis.

Authors:  F Cosman; S J de Beur; M S LeBoff; E M Lewiecki; B Tanner; S Randall; R Lindsay
Journal:  Osteoporos Int       Date:  2014-08-15       Impact factor: 4.507

10.  Prevalence of Osteoporosis and Low Bone Mass in Older Chinese Population Based on Bone Mineral Density at Multiple Skeletal Sites.

Authors:  Yi-Chien Lu; Ying Chin Lin; Yen-Kuang Lin; Yi-Jui Liu; Kwang-Hwa Chang; Poon-Ung Chieng; Wing P Chan
Journal:  Sci Rep       Date:  2016-05-04       Impact factor: 4.379

View more
  1 in total

1.  Establishment of a preliminary FRAX®-based intervention threshold for rheumatoid arthritis-associated fragility fracture: a 3-year longitudinal, observational, cohort study.

Authors:  Shan-Fu Yu; Ming-Han Chen; Jia-Feng Chen; Yu-Wei Wang; Ying-Chou Chen; Chung-Yuan Hsu; Han-Ming Lai; Wen-Chan Chiu; Chi-Hua Ko; Hsiao-Ru He; Tien-Tsai Cheng
Journal:  Ther Adv Chronic Dis       Date:  2022-02-25       Impact factor: 5.091

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.